Conference Day One
Wednesday, May 22, 2024
8:00 am Registration & Refreshments
8:55 am Chair’s Opening Remarks
Forming Synergies Between Pharma and Biotech Collaborations to Redefine the Treg Landscape and Accelerate Clinical Development
9:00 am Panel Discussion– Navigating the Future Landscape of Treg Directed Therapies: Collaborations, Challenges & Breakthroughs
Synopsis
An interactive panel discussion from the industry leaders of the field to set the scene on the Treg therapy space. Ask your questions live to understand the expert’s thoughts on key topics including:
- Bridging the evolving landscape of Treg directed therapies
- How can we ensure academia and industry are collaborating effectively for mutual benefit
- Recent breakthroughs that are shaping the Treg therapy industry
9:30 am TRB-061: A ‘Next-Gen’ Treg Augmenter for I&I Disea
Synopsis
- TNFR2 is highly expressed on immunosuppressive Treg in inflamed tissues.
- TRB-061, a TNFR2-selective agonist, shows potent in vitro and in vivo Treg augmentation, providing protection in preclinical models of inflammation.
- Our ‘Deep Biology Platform’ revealed the molecular details of TNFR2 agonism on Treg allowing for the design of an optimal agonist molecule and suggests differentiated clinical opportunities in inflammatory and autoimmune diseases
10:00 am Empowering Innovation & Forming Strategic Collaborations for Advancing Novel Treg Therapies
Synopsis
- Discussing the critical need for identifying the right partners to propel novel Treg therapies forward
- Addressing the financial challenges faced by biotech’s, providing key insights on navigating challenges to build collaborative relationships including shared goals to support the transition into clinical phases
- Exploring potential collaborators and how small biotech’s can form a symbiotic relationship with large pharma to progress clinical pipelines
10:30 am Morning Refreshments & Speed Networking
Synopsis
As the Treg community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the two different tracks: Cell-Based, Non-Cell Based
Cell-Based Approaches
Enhancing Clinical Data in Treg therapies to Transform Future Pipeline Development
11:30 am Unlock Treg Epitopes: A Unifying Mechanism for Modulating the Immune Response
Synopsis
- Treg epitopes activating natural Tregs contribute to the expansion of antigen specific Tregs and modulation of B cell responses
- Treg epitopes may represent the unifying mechanism of action of IVIG and FcRN blockers
- Modification and/or introduction of Treg epitopes into therapeutics should consider individual HLA restrictions
12:00 pm Through the generations of Treg Products – promises, successes, and failures
Synopsis
- The path from laboratory to GMP-compliant site to produce clinical-stage Tregs
- Tregs physiology matters – features of Treg product which influence safety and efficacy
- How the disease dictates the use of particular Treg products
- How to scale up? Autologous , allogeneic, CAR, TCR, antigen-specific, polyclonal or all…
12:30 pm Tailoring Treg Therapies Using Precision Modifications to Enhance Therapeutic Efficacy
Synopsis
- Outlining the limitations of generic approaches and the need for tailored interventions for patient specificity
- (Case study) an overview precision engineering of Treg cells with key insights into lessons learned and exploring the potential for broader applications in diverse disease states
Non-Cell Based Approaches
Utilizing Novel Platform Technology to Amplify Treg Induction In-Vivo
11:30 am Revitalizing Treg Function in Autoimmunity: An Innovative Protein Drug Conjugate Platform
Synopsis
- IL-2Rx has developed a platform of IL-2 fusion protein-based therapeutics known as Protein Drug Conjugates (PDC) designed to restore Treg function in autoimmunity
- These PDCs carry detachable small molecule neddylation activating enzyme inhibitors, that restore or enhance autoimmune Treg function
12:00 pm Reserved for Revolo Biotherapeutics
Synopsis
Session details TBC
12:30 pm Increasing the Therapeutic Window of Engineered Interleukin-2 & Driving Expansion of Antigen-Specific Regulatory T cells with ImmTOR Tolerogenic Nanoparticles
Synopsis
- IL-2 can be engineered to increase its half-life and selectivity for Tregs; however, selectivity can be reduced at higher doses and in settings of activated effector cells
- ImmTOR nanoparticles loaded with rapamycin acts synergistically with engineered IL-2 to increase expansion Tregs while mitigating effector cell activation
- Engineered IL-2 combined with ImmTOR also acts synergistically to enhance induction of antigen-specific Tregs for protection against autoimmune disease
1:00 pm Lunch Break & Networking
Cell-Based Approaches
Enhancing Clinical Data in Treg therapies to Transform Future Pipeline Development
2:00 pm Why has Cell Therapy Failed?
Synopsis
- The results of phase III trials in cell therapy have been disappointing
- The reason is because the expensive ex vivo manipulation or engineering of cells out of the body diminishes in vivo function. This applies to Treg therapy
- Tregs produce energy via glucokinase, activation of which increases migration of Tregs to sites of inflammation in vivo
2:30 pm Understanding the Complexity of Tregs in Autoimmunity & Cancer, & Manipulting Tegs In Vivo for Immunotherapy
Synopsis
- Novel approach to inducing autoantigen specific Tregs in vivo for treatment of autoimmunity
- Car-T mediated therapy in autoimmune diseases: do Tregs play a role?
- Unique features of Tregs in tumour tissues; what happened for intratumor Tregs in check-point blockade antibodymediated immunotherapy in cancer
3:00 pm Reserved for Barinthus Biotherapeutics
Synopsis
Session details TBC
Non-Cell Based Approaches
Measuring Treg Dynamics in Clinical Settings, Addressing the involvement of IL2 & Overcoming Challenges to Enhance the IL-2 Approach
2:00 pm Low-Dose IL-2/CD25 Remodels Inflamed Tissues to Limit Autoimmunity
Synopsis
- Molecular and functional properties of IL-2/CD25
- Effects of IL-2/CD25 on the immune landscape in inflamed pancreatic islets
- 3) IL-2/CD25 contributes to improved b-cell function
2:30 pm Navigating the Interplay of IL2 & Treg Cells for Therapeutic Success
Synopsis
- Introducing the pivotal role of IL2 in Treg functionality to explore the impact of IL2 based therapies
- Exploring means to provide IL-2 to Tregs to improve their survival, stability and functionality
- Exploring the potential of providing Tregs with additional functions (e.g boosting IL-10)
3:00 pm Enhancing the therapeutic potential of engineered Treg Therapies
Synopsis
The talk will focus on maximizing the Therapeutic potential of Treg products though enhancing the
- Homing to sites of immune modulation
- Enhancing persistence in the tissues
- Enhancing durability
- Delivering specific immunomodulatory and tissue repair payloads
3:30 pm Afternoon Break & Poster Session
Harmonizing Cell-Based & Non-Cell Based Approaches with Selected Disease Targets for Offthe-shelf Therapies
4:30 pm Panel Discussion: Spearheading Acceleration of Next Generation Treg Therapies by Integrating Cell Based & Non Cell Based Approaches
Synopsis
- Highlighting the potential synergies and challenges with combining these two approaches and how this would positively impact future therapies
- Exploring successful examples of combination approaches to enhance current treatments
- Discussing regulatory considerations and approval pathways for combination therapies to address how this may impact therapeutic development
5:00 pm Reviewing Treg in Autoimmunity
Synopsis
- Treg instability and fragility in autoimmune disease
- Treg resistance in autoimmune diseases
5:30 pm Immunometabolites as Checkpoints That Regulate Immunity
Synopsis
- Immunometabolites are effective checkpoints that regulate immunity
- Specific targeting of select metabolic nodes drives regulatory T cell expansion and is associated with efficacy in a humanized model of GVHD